By providing 12 weeks of alogliptin treatment, Shah et al. demonstrated that DPP4 inhibition reduced atherosclerotic plaque and vascular inflammation in atherosclerosis prone Ldlr−/− and ApoE−/− mice [134]. This evidence concerns the gene DPP4 and atherosclerosis.